Braidwell LP Raises Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Braidwell LP lifted its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 167.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,894,439 shares of the company's stock after buying an additional 1,187,199 shares during the period. Braidwell LP owned approximately 4.68% of Keros Therapeutics worth $29,989,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. increased its stake in Keros Therapeutics by 585.9% in the 4th quarter. JPMorgan Chase & Co. now owns 213,431 shares of the company's stock worth $3,379,000 after purchasing an additional 182,314 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Keros Therapeutics during the fourth quarter worth about $388,000. Darwin Global Management Ltd. grew its stake in shares of Keros Therapeutics by 10.7% in the fourth quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company's stock worth $26,707,000 after purchasing an additional 163,403 shares during the last quarter. Barclays PLC increased its holdings in Keros Therapeutics by 140.1% during the 3rd quarter. Barclays PLC now owns 60,014 shares of the company's stock valued at $3,484,000 after purchasing an additional 35,022 shares during the period. Finally, Norges Bank bought a new position in Keros Therapeutics during the 4th quarter valued at approximately $1,027,000. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Stock Performance

Shares of KROS stock traded down $0.37 on Friday, reaching $13.65. The stock had a trading volume of 546,340 shares, compared to its average volume of 821,754. Keros Therapeutics, Inc. has a 1 year low of $9.12 and a 1 year high of $72.37. The stock has a market cap of $554.39 million, a P/E ratio of -2.62 and a beta of 1.32. The company has a 50 day simple moving average of $12.20 and a 200 day simple moving average of $24.71.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, beating the consensus estimate of ($0.01) by $3.63. The firm had revenue of $211.25 million during the quarter, compared to analyst estimates of $84.62 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. During the same quarter in the prior year, the firm earned ($1.21) EPS. On average, equities research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The stock was bought at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the purchase, the insider now owns 4,392,737 shares in the company, valued at $44,498,425.81. The trade was a 27.01 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 20.60% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on KROS. Cantor Fitzgerald downgraded shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Tuesday, January 21st. Wells Fargo & Company lowered their target price on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, February 27th. Guggenheim reaffirmed a "neutral" rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Oppenheimer lowered their price objective on Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a research report on Thursday, January 16th. Finally, Wedbush reissued a "neutral" rating and issued a $15.00 price target on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $38.67.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.